BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 27629777)

  • 1. Promoter DNA methylation of CDO1 gene and its clinical significance in esophageal squamous cell carcinoma.
    Ushiku H; Yamashita K; Katoh H; Ema A; Minatani N; Kikuchi M; Kojo K; Yokoi K; Tanaka T; Nishizawa N; Ishii S; Hosoda K; Moriya H; Mieno H; Katada N; Kikuchi S; Watanabe M
    Dis Esophagus; 2017 Feb; 30(2):1-9. PubMed ID: 27629777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic regulation of the novel tumor suppressor cysteine dioxygenase 1 in esophageal squamous cell carcinoma.
    Kwon J; Park M; Kim JH; Lee HW; Kang MC; Park JH
    Tumour Biol; 2015 Sep; 36(10):7449-56. PubMed ID: 25903467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical significance of cysteine dioxygenase type 1 methylation in Barrett esophagus adenocarcinoma.
    Kojima K; Yamashita K; Ushiku H; Katoh H; Ishii S; Tanaka T; Yokoi K; Suzuki M; Ooizumi Y; Igarashi K; Hosoda K; Moriya H; Mieno H; Katada N; Tanabe S; Watanabe M
    Dis Esophagus; 2017 Mar; 30(3):1-9. PubMed ID: 28184414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of promoter DNA hypermethylation of the cysteine dioxygenase 1 (CDO1) gene in primary gallbladder cancer and gallbladder disease.
    Igarashi K; Yamashita K; Katoh H; Kojima K; Ooizumi Y; Nishizawa N; Nishiyama R; Kawamata H; Tajima H; Kaizu T; Kumamoto Y; Watanabe M
    PLoS One; 2017; 12(11):e0188178. PubMed ID: 29161283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Significance of Promoter DNA Hypermethylation of cysteine dioxygenase 1 (CDO1) Gene in Primary Breast Cancer.
    Minatani N; Waraya M; Yamashita K; Kikuchi M; Ushiku H; Kojo K; Ema A; Nishimiya H; Kosaka Y; Katoh H; Sengoku N; Tanino H; Sidransky D; Watanabe M
    PLoS One; 2016; 11(1):e0144862. PubMed ID: 26785325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-specific promoter DNA methylation of Cysteine dioxygenase type 1 (CDO1) gene as an important prognostic biomarker of gastric cancer.
    Harada H; Hosoda K; Moriya H; Mieno H; Ema A; Ushiku H; Washio M; Nishizawa N; Ishii S; Yokota K; Tanaka Y; Kaida T; Soeno T; Kosaka Y; Watanabe M; Yamashita K
    PLoS One; 2019; 14(4):e0214872. PubMed ID: 30934021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodality Treatment and Prognosis in Esophageal Squamous Cell Carcinoma Requiring Esophagectomy.
    Yamashita K; Katada N; Moriya H; Hosoda K; Sakuramoto S; Kikuchi S; Watanabe M
    Hepatogastroenterology; 2014 Jun; 61(132):1042-8. PubMed ID: 26158163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.
    Hamai Y; Hihara J; Emi M; Furukawa T; Ibuki Y; Yamakita I; Kurokawa T; Okada M
    Anticancer Res; 2017 Oct; 37(10):5639-5646. PubMed ID: 28982881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic CpG methylation biomarkers identified by methylation array in esophageal squamous cell carcinoma patients.
    Kuo IY; Chang JM; Jiang SS; Chen CH; Chang IS; Sheu BS; Lu PJ; Chang WL; Lai WW; Wang YC
    Int J Med Sci; 2014; 11(8):779-87. PubMed ID: 24936140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant hypermethylation of RASSF2 in tumors and peripheral blood DNA as a biomarker for malignant progression and poor prognosis of esophageal squamous cell carcinoma.
    Guo W; Dong Z; Cui J; Guo Y; Shen S; Guo X; Kuang G
    Clin Exp Metastasis; 2016 Jan; 33(1):73-85. PubMed ID: 26482475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced expression of DENND2D through promoter hypermethylation is an adverse prognostic factor in squamous cell carcinoma of the esophagus.
    Hibino S; Kanda M; Oya H; Takami H; Shimizu D; Nomoto S; Hishida M; Niwa Y; Koike M; Yamada S; Nishikawa Y; Asai M; Nakayama G; Fujii T; Sugimoto H; Fujiwara M; Kodera Y
    Oncol Rep; 2014 Feb; 31(2):693-700. PubMed ID: 24317529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Prognostic Relevance of Promoter DNA Methylation of
    Tanaka Y; Kosaka Y; Waraya M; Yokota K; Harada H; Kaida T; Kikuchi M; Minatani N; Nishimiya H; Katoh H; Sengoku N; Watanabe M; Yamashita K
    Anticancer Res; 2019 May; 39(5):2289-2298. PubMed ID: 31092420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endoglin promoter hypermethylation identifies a field defect in human primary esophageal cancer.
    Jin Z; Zhao Z; Cheng Y; Dong M; Zhang X; Wang L; Fan X; Feng X; Mori Y; Meltzer SJ
    Cancer; 2013 Oct; 119(20):3604-9. PubMed ID: 23893879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-reactive protein to albumin ratio is a prognostic factor for patients with cStage II/III esophageal squamous cell cancer.
    Otowa Y; Nakamura T; Yamamoto M; Kanaji S; Matsuda Y; Matsuda T; Oshikiri T; Sumi Y; Suzuki S; Kakeji Y
    Dis Esophagus; 2017 Dec; 30(12):1-5. PubMed ID: 28881893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylated promoter DNA of CDO1 gene and preoperative serum CA19-9 are prognostic biomarkers in primary extrahepatic cholangiocarcinoma.
    Nakamoto S; Kumamoto Y; Igarashi K; Fujiyama Y; Nishizawa N; Ei S; Tajima H; Kaizu T; Watanabe M; Yamashita K
    PLoS One; 2018; 13(10):e0205864. PubMed ID: 30325974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylation of RASSF1A gene promoter and the correlation with DNMT1 expression that may contribute to esophageal squamous cell carcinoma.
    Du Z; Ma K; Sun X; Li A; Wang H; Zhang L; Lin F; Feng X; Song J
    World J Surg Oncol; 2015 Apr; 13():141. PubMed ID: 25886188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
    Yamashita K; Katada N; Moriya H; Hosoda K; Mieno H; Katada C; Koizumi W; Hoshi K; Watanabe M
    Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):209-15. PubMed ID: 26868531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of neutropenia and histological responses in esophageal squamous cell carcinoma with neo-adjuvant chemotherapy.
    Konishi H; Fujiwara H; Shiozaki A; Hiramoto H; Kosuga T; Komatsu S; Ichikawa D; Okamoto K; Otsuji E
    Int J Clin Oncol; 2016 Feb; 21(1):95-101. PubMed ID: 26194809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.
    Meller S; Zipfel L; Gevensleben H; Dietrich J; Ellinger J; Majores M; Stein J; Sailer V; Jung M; Kristiansen G; Dietrich D
    Epigenetics; 2016 Dec; 11(12):871-880. PubMed ID: 27689475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.